Roche

News

Genentech buys Regor's next-gen CDK inhibitors for $850M

Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.

News

Roche's PNH drug PiaSky backed for NHS use by NICE

Roche's PiaSky has been recommended for use by the NHS in England and Wales for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH), becoming the first option for patients th

News

Roche launches 'revolutionary' pathogen detection tech

Roche has introduced the first test based on a new technology – called TAGS – that it believes could revolutionise testing for infectious diseases by allowing high-throughput detection to b

News

WCLC: Biomarker could guide Dato-DXd use in lung cancer

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dat

News

Roche trumpets new fenebrutinib data in relapsing MS

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (M

News

Roche gets EU nod for subcutaneous PNH drug PiaSky

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcu

Genentech buys Regor's next-gen CDK inhibitors for $850M

Roche's PNH drug PiaSky backed for NHS use by NICE

Roche launches 'revolutionary' pathogen detection tech

WCLC: Biomarker could guide Dato-DXd use in lung cancer

Roche trumpets new fenebrutinib data in relapsing MS

Roche gets EU nod for subcutaneous PNH drug PiaSky

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks